Post-Brexit, What Does the Future Hold for Pharma?
Since the fateful Brexit vote of June 2016 – where the citizens of the United Kingdom voted to leave the European Union in an advisory referendum... In DRG Blog/ March, 2018 EU HTA Cooperation: Market Access Challenge or Opportunity?
As our colleagues at DRG Abacus recently discussed, in January 2018, the European Commission (EC) unveiled a proposal to increase health... In DRG Blog/ March, 2018 Market Access Challenges in 2017: Healthcare Reform in Poland
Though all eyes may be on the looming healthcare reforms in the United States under the new Trump administration, a fairly new government in Poland... In DRG Blog/ March, 2017 Market Access Challenges in 2017: Uncertainty Looming Over Russian Market
Recent years in Russia have been increasingly turbulent, and not just in the political realm. Low oil prices, economic sanctions, and currency... In DRG Blog/ March, 2017 After the Brexit Referendum: Where Does the UK Go from Here?
When I wrote about a potential Brexit looming over the pharmaceutical industry a few weeks ago, I had hoped that the blog would be a purely... In DRG Blog/ June, 2016 Paying for Performance: EFPIA’s Catch-22 for European Drug Pricing
A leaked internal paper could signal a tidal shift in European drug pricing as companies and payers continue their combined march toward value-... In DRG Blog/ June, 2016 UK: Fear of Brexit Looming Over Pharma
In just a few weeks, Britain’s uneasy relationship with the Continent will face its trickiest test in decades – one whose outcome will have a... In DRG Blog/ June, 2016 Russia: Capricious or Compulsory Licensing?
Though compulsory licensing of pharmaceuticals in the BRICS (Brazil, Russia, India, China, and South Africa) is quite commonplace, Russia has... In DRG Blog, Market Access/ May, 2016 UK Cancer Drugs Fund Reform: Will It Be Enough?
Though most would acknowledge that the United Kingdom’s Cancer Drugs Fund (CDF) was in desperate need of reform once the current structure... In DRG Blog, Market Access/ March, 2016 Oil and Healthcare: Global Crises Hitting Russians at Home
The freefall of oil prices could not have come at a worse time for Russia. Initially, it seemed like healthcare would be spared the price of Putin... In DRG Blog, Market Access/ March, 2016 Pharma 2020: Russia Marching Towards Self-sufficiency?
Although perhaps better known outside its borders these days for foreign policy moves, Russia has quietly become one of the most dynamic market... In DRG Blog, Market Access/ January, 2016